Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Vico Therapeutics | Leiden | Series B | $12.3M | 2024-06-24 |
| PanTera | Mol | Series A | $110.3M | 2024-09-11 |
| Shinobi Therapeutics | South San Francisco | Series A | $68.0M | 2024-08-06 |
| VectorY | Amsterdam | Series A | $138.0M | 2023-11-13 |
| Onera Health | Eindhoven | Series C | $32.6M | 2024-01-16 |
| FoRx Therapeutics | Basel | Series A | $50.0M | 2025-12-18 |
| Binx Health | Boston | Series F | $65.0M | 2024-04-02 |
| Cardior Pharmaceuticals | Hanover | Series B | $75.3M | 2021-08-25 |
8 rows of the CSV in 5 of its 18 columns.
- The 23 EQT Life Sciences portfolio companies have raised $1.6B in total.
- 1 of them closed their most recent round in the last 12 months, $50.0M combined.
- The largest of those rounds is FoRx Therapeutics' $50.0M Series A, dated December 2025.
- Andera Partners is an investor in 4 of them, more than any other fund.
- Health care is the most common sector, with 19 companies (83%).
- 17% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 11 to 50 employees (61% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
17 of 23| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| FoRx Therapeutics | FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. | Biotech | Basel, Switzerland | Series A | $50.0M | 2025-12-18 | $109.4M | EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 | 11 to 50 | 2019 |
| SNIPR Biome | SNIPR Biome develops discovery-stage biotech treatments for microbial diseases. | Biotech | Copenhagen, Denmark | Series B | $40.9M | 2025-08-07 | $103.4M | Wellington Partners, Bill & Melinda Gates Foundation, EQT Life Sciences +1 | 11 to 50 | 2017 |
| PanTera | PanTera produces actinium-225 for personalized cancer treatment and radiopharmaceuticals. | Health care | Mol, Belgium | Series A | $110.3M | 2024-09-11 | Eurazeo, PMV, EQT Life Sciences +2 | 11 to 50 | 2022 | |
| Shinobi Therapeutics | Shinobi Therapeutics develops immune-evasive iPS cell therapies for cancer treatment. | Biotech | South San Francisco, United States | Series A | $68.0M | 2024-08-06 | $178.0M | Mitsubishi UFJ Capital, F-Prime, EQT Life Sciences +2 | 11 to 50 | 2023 |
| Asceneuron | Asceneuron develops therapeutics for orphan tauopathies and Alzheimer's disease. | Biotech | Lausanne, Switzerland | Series C | $100.0M | 2024-07-16 | OrbiMed, Novo Holdings, EQT Life Sciences +1 | 1 to 10 | 2012 | |
| Vico Therapeutics | Vico Therapeutics develops RNA modulating therapies. | Biotech | Leiden, The Netherlands | Series B | $12.3M | 2024-06-24 | $115.4M | Polaris Partners, Eurazeo, EQT Life Sciences +2 | 11 to 50 | 2019 |
| Phagenesis | Phagenesis develops a device that treats dysphagia, a condition that makes swallowing food unsafe. | Biotech | Manchester, United Kingdom | Series D | $42.0M | 2024-03-04 | $71.4M | MedTech Innovator, EQT Life Sciences, Northern Gritstone +2 | 11 to 50 | 2007 |
| Onera Health | Onera Health provides sleep diagnostics and monitoring products for clinical and home use. | Hardware | Eindhoven, The Netherlands | Series C | $32.6M | 2024-01-16 | $57.0M | European Innovation Council, EQT Life Sciences, Gimv +1 | 11 to 50 | 2017 |
| LUMA Vision | LUMA Vision develops 4D cardiac imaging and navigation technology for point-of-therapy data delivery. | Health care | Harold's Cross, Ireland | Series A | $21.8M | 2023-12-18 | $54.0M | Enterprise Ireland, European Innovation Council, Bayern Kapital +2 | 51 to 100 | 2017 |
| VectorY | VectorY develops gene therapies for central nervous system, somatic, and muscle diseases. | Biotech | Amsterdam, The Netherlands | Series A | $138.0M | 2023-11-13 | $175.6M | Insight Partners, Benhamou Global Ventures, Forbion Capital Partners +2 | 51 to 100 | 2020 |
| Cardior Pharmaceuticals | Cardior Pharmaceuticals develops medicines and therapies to treat and prevent heart disease. | Biotech | Hanover, Germany | Series B | $75.3M | 2021-08-25 | HTGF (High-Tech Gruenderfonds), EQT Life Sciences, Bristol-Myers Squibb +2 | 11 to 50 | 2016 | |
| Arvelle Therapeutics | Arvelle Therapeutics is a biopharmaceutical company developing medicines for patients. | Biotech | Basel, Switzerland | Series A | $42.7M | 2020-05-27 | KB Investment, F-Prime, EQT Life Sciences +2 | 51 to 100 | 2019 | |
| Endotronix | Endotronix develops hemodynamic monitoring technologies that detect worsening heart failure earlier. | Biotech | Lisle, United States | Series D | $70.0M | 2018-09-14 | $129.6M | Silicon Valley Bank, JumpStart Inc., EQT Life Sciences +1 | 101 to 250 | 2007 |
| Luxendo | Luxendo develops and manufactures proprietary light-sheet fluorescence microscopy instruments. | Biotech | Heidelberg, Germany | Series A | $8.5M | 2017-01-12 | EQT Life Sciences, EMBL Ventures, LSP BioVentures | 11 to 50 | 2015 | |
| Okairos | Okairos develops genetic T-cell vaccines, including candidates targeting hepatitis C virus. | Biotech | Basel, Switzerland | Series B | $20.5M | 2010-09-14 | $30.1M | EQT Life Sciences, Versant Ventures, Novartis Venture Fund +2 | 1 to 10 | 2007 |
| Vivendy Therapeutics | Vivendy Therapeutics develops enzyme replacement therapies. | Biotech | Basel, Switzerland | Series B | $30.5M | 2008-06-23 | EQT Life Sciences, BioMedPartners, TVM Capital +1 | 11 to 50 | 2006 | |
| 4-Antibody AG | 4-Antibody AG develops a human antibody drug-discovery platform for immuno-oncology therapeutics. | Biotech | Basel, Switzerland | Series A | $18.4M | 2007-01-16 | $20.6M | EQT Life Sciences, BioMedPartners, Grazia Equity +2 | 251 to 500 | 2002 |
Table 1. EQT Life Sciences portfolio companies: the 17 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 23.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | FoRx Therapeutics | FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. | Biotech | Basel, Switzerland | Series A | $50.0M | 2025-12-18 | $109.4M | EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 | 11 to 50 | 2019 |
Table 2. EQT Life Sciences portfolio companies: the 1 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Andera Partners | Private equity firm | Paris, France | 4 | 17% | ||
| 2 | Novartis Venture Fund | Corporate venture arm | Basel, Switzerland | 3 | 13% | 1 | FoRx Therapeutics |
| 3 | BioMedPartners | Venture capital firm | Basel, Switzerland | 3 | 13% | ||
| 4 | Eurazeo | Private equity firm | Paris, France | 2 | 9% | ||
| 5 | Kurma Partners | Venture capital firm | Paris, France | 2 | 9% | ||
| 6 | F-Prime | Venture capital firm | Cambridge, United States | 2 | 9% | ||
| 7 | European Innovation Council | Startup accelerator | Brussels, Belgium | 2 | 9% | ||
| 8 | OrbiMed | Private equity firm | New York, United States | 2 | 9% | ||
| 9 | Boehringer Ingelheim Venture Fund | Corporate venture arm | Ingelheim Am Rhein, Germany | 2 | 9% | ||
| 10 | Inkef | Venture capital firm | Amsterdam, The Netherlands | 2 | 9% | ||
| 11 | Versant Ventures | Venture capital firm | Menlo Park, United States | 2 | 9% | ||
| 12 | Novo Holdings | Corporate venture arm | Hellerup, Denmark | 2 | 9% | ||
| 13 | Bayern Kapital | Venture capital firm | Landshut, Germany | 2 | 9% | ||
| 14 | Sectoral Asset Management | Private equity firm | Montréal, Canada | 2 | 9% | ||
| 15 | Wellington Partners | Venture capital firm | Munich, Germany | 2 | 9% |
Table 3. EQT Life Sciences portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 19 | 83% | $1.5B |
| Biotech | 18 | 78% | $1.1B |
| Software | 3 | 13% | $283.4M |
| Hardware | 2 | 9% | $186.6M |
Table 4. EQT Life Sciences portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. EQT Life Sciences portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| Switzerland | 6 | 26% |
| Germany | 6 | 26% |
| United States | 4 | 17% |
| The Netherlands | 3 | 13% |
| Belgium | 1 | 4% |
| Ireland | 1 | 4% |
| United Kingdom | 1 | 4% |
| Denmark | 1 | 4% |
Table 6. EQT Life Sciences portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Basel | 5 | 22% |
| Berlin | 2 | 9% |
| Leiden | 1 | 4% |
| Mol | 1 | 4% |
| South San Francisco | 1 | 4% |
| Amsterdam | 1 | 4% |
| Eindhoven | 1 | 4% |
| Boston | 1 | 4% |
| Hanover | 1 | 4% |
| Lausanne | 1 | 4% |
| Harold's Cross | 1 | 4% |
| Manchester | 1 | 4% |
Table 7. EQT Life Sciences portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| December 2025 | 1 | 100% | $50.0M |
Table 8. EQT Life Sciences portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2025 | 2 | 9% | $90.9M |
| 2024 | 7 | 30% | $430.3M |
| 2023 | 3 | 13% | $184.9M |
| 2021 | 2 | 9% | $185.3M |
| 2020 | 1 | 4% | $42.7M |
| 2018 | 2 | 9% | $90.0M |
Table 9. EQT Life Sciences portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 1 | 4% |
| 2020 to 2022 | 3 | 13% |
| 2015 to 2019 | 9 | 39% |
| 2010 to 2014 | 3 | 13% |
| Before 2010 | 7 | 30% |
Table 10. EQT Life Sciences portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 2 | 9% |
| 11 to 50 | 14 | 61% |
| 51 to 100 | 5 | 22% |
| 101 to 250 | 1 | 4% |
| 251 to 500 | 1 | 4% |
Table 11. EQT Life Sciences portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when EQT Life Sciences is recorded as one of its investors. On 16 November 2026 that is 23 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 17 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 23 rows: 0 have no round amount, 0 no city and 3 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many EQT Life Sciences portfolio companies are on the list?
- 23, in the file dated 16 November 2026. 1 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 23 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.